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Edited by Amy McGoughAbstract Adenosine 5 0-monophosphate (AMP) inhibits muscle
fructose 1,6-bisphosphatase (FBPase) about 44 times stronger
than the liver isozyme. The key role in strong AMP binding to
muscle isozyme play K20, T177 and Q179. Muscle FBPase
which has been mutated towards the liver enzyme (K20E/
T177M/Q179C) is inhibited by AMP about 26 times weaker
than the wild-type muscle enzyme, but it binds the ﬂuorescent
AMP analogue, 2 0,3 0-O-(2,4,6-trinitrophenyl)adenosine 5 0-
monophosphate (TNP-AMP), similarly to the wild-type liver en-
zyme. The reverse mutation of liver FBPase towards the muscle
isozyme signiﬁcantly increases the aﬃnity of the mutant to
TNP-AMP. High aﬃnity to the inhibitor but low sensitivity to
AMP of the liver triple mutant suggest diﬀerences between the
isozymes in the mechanism of allosteric signal transmission.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Fructose 1,6-bisphosphatase (FBPase, EC 3.1.3.11) catalyzes
hydrolysis of fructose 1,6-bisphosphate (F1,6-P2) to fructose 6-
phosphate (F6-P) and inorganic phosphate in the presence of
such divalent metal ions as: Mg2+, Mn2+, Co2+ and Zn2+
[1,2]. Contrary to previously mentioned divalent cations,
Ca2+ inhibits FBPase activity [3,4]. Both mammalian FBPase
isozymes – liver and muscle – are activated by monovalent
cations [1,2,5,6] and are inhibited competitively by fructose
2,6-bisphosphate (F2,6-P2) and allosterically by Adenosine
5 0-monophosphate (AMP) [1,2,5–8].
Mammalian FBPases are homotetrameric enzymes with a
subunit molecular weight of about 37 kDa [9–12]. The tertiary
structure of each monomer is composed of two domains, the
F1,6-P2 domain containing the active site and the AMP do-
main with the AMP binding site.Abbreviations: FBPase, fructose 1,6-bisphosphatase; F1,6-P2, fructose
1,6-bisphosphate; F2,6-P2, fructose 2,6-bisphosphate; PFK, phospho-
fructokinase; TNP-AMP, 2 0,3 0-O-(2,4,6-trinitrophenyl)adenosine 50-
monophosphate
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coneogenesis. Proposed functions of the muscle isozyme are
participation in glycogen synthesis from lactate [13,14] and
regulation of glycolysis via futile cycle which may be formed
with phosphofructokinase (PFK) [15]. The basic diﬀerence in
the kinetic properties of the liver and muscle isozymes con-
cerns their sensitivity to calcium ions [3,4] and to AMP inhibi-
tion [2,16–18]. In case of the muscle enzyme I0.5 for AMP is
about 0.1 lM, i.e., 50–100 times lower than the corresponding
value determined for liver FBPase. The high sensitivity of mus-
cle FBPase indicates that the isozyme should be almost com-
pletely inhibited in vivo [19–21].
Recently, we have shown that interaction of muscle FBPase
with muscle aldolase in vitro results in the formation of a com-
plex in which FBPase is entirely insensitive to AMP inhibition
[20,22] and strongly desensitized to Ca2+ inhibition [4] and
F1,6-P2 is transferred directly from aldolase to FBPase [22].
It is presumed that sarcomere-bound FBPase interacts with
aldolase and other glyconeogenic enzymes forming a multien-
zyme complex within the region of the Z-line which synthesizes
glycogen from carbohydrate precursors [4,22–24]. On the other
hand, the fraction of uncomplexed FBPase is supposed to in-
crease during acceleration of glycolysis [20]. Thus, the high
sensitivity of free FBPase to AMP inhibition seems to be a
mechanism preventing muscle cells from dissipating energy
via futile cycling between PFK and FBPase during muscle con-
traction [4,25].
The molecular basis of high sensitivity of muscle FBPase to
AMP inhibition is unknown. Recently, we hypothesized that
the key role in stronger AMP binding to the muscle isozyme
is played by K20, T177 and Q179 which allow the formation
of new hydrogen bonds to the inhibitor [21]. In the present re-
port, we provide experimental data demonstrating the crucial
role of residues 20, 177 and 179 for a diﬀerent binding of
AMP to liver and muscle FBPase. Our results also suggest that
an additional mechanism connected with allosteric signal
transmission in muscle FBPase must account for the strong
inhibition of the muscle enzyme.2. Materials and methods
Phosphocellulose P-11 was purchased from Whatman (Maidstone,
England), ammonium sulfate and Coomassie Brilliant Blue were from
Fluka (Buchs, Switzerland). 2 0-(or-3 0)-O-(trinitrophenyl) adenosine 5 0-
monophosphate, sodium salt (TNP-AMP) was from Molecular Probes
(Eugene, USA). Nucleic acid modifying enzymes and restrictionation of European Biochemical Societies.
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Sigma (St. Louis, USA). All the reagents were of the highest purity
commercially available.
The Escherichia coli strain XL1-Blue MRF Kan (Stratagene, La Jol-
la, USA) was used for transformation, propagation and isolation of
plasmids as well as for expression of recombinant FBPases and was
grown in Luria Broth at 37 C supplemented with 100 lg/ml ampicillin
[26].
Plasmid isolation, DNA restriction endonuclease analysis, ligation,
and transformation were performed as described [26]. Either a Qiaprep
spin miniprep kit or Qiaquick gel extraction kit (Qiagen, Hilden, Ger-
many) was used to prepare plasmid DNA for restriction enzyme diges-
tion, sequencing, and recovering DNA fragments from agarose gels.
The sequence of each mutant gene product was conﬁrmed by Sanger
DNA sequencing on an ABI 377 sequencer using the Big Dye Termi-
nator Cycle Sequencing Kit (Applied Biosystems, Foster City, USA).
Mutations in the sequence of human liver and humanmuscle FBPases
were introduced by site-directed mutagenesis using the QuikChangee
site-directedmutagenesis procedure (Stratagene). Primers used for intro-
duction of the M177T/C179Q and T177M/Q179C mutations into the
liver and muscle FBPase, respectively, were: M177/C179 5 0-TGGC-
TCTCTCCATGGGGTGTGGCGTGGACCTC-3 0 and T177/Q179
5 0-CTGGTCCTTGCCACAGACCAAGGGGTCAACTGCTT-3 0.
Plasmids containing single mutations E20K and K20E prepared as
described previously [21] were used as template for creating triple mu-
tants E20K/M177T/C179Q and K20E/T177M/Q179C of human liver
and muscle FBPase, respectively.
Protein expression and puriﬁcation were performed as described pre-
viously [21]. Protein purity and concentration throughout the puriﬁca-
tion procedure were monitored by SDS–PAGE and Bradford assays,
respectively.
TNP-AMP titration of recombinant FBPases was performed
according to Nelson et al. [27] using 0.5 lM concentration of FBPase.
Data were analyzed by non-linear regression analysis using the follow-
ing equation:
DF =DF max ¼ Ln=Kd þ Ln;
where DF is the increase of ﬂuorescence caused by addition of ligand
L (DF = Fsample  (ﬂuorescence of FBPase + ﬂuorescence of TNP-
AMP)), DFmax is the maximal increase of ﬂuorescence caused by
addition of the ligand, Kd is dissociation constant and n is the Hill
coeﬃcient.
Fluorescence data were collected using a HITACHI F4500 ﬂuores-
cence spectrophotometer. All kinetic experiments were performed at
pH 7.5 and 37 C using a glucose 6-phosphate isomerase–glucose 6-
phosphate dehydrogenase coupled spectrophotometric assay [28].
The reactions were started with saturating concentration of F1,6-P2
(35 lM). One unit of enzyme activity is deﬁned as the amount of the
enzyme that catalyses the formation of 1 lmol of product per minute.
Spectrophotometric measurements were performed with an Agilent
8453 diode array spectrophotometer. Determination of I0.5, Hill coef-
ﬁcient for AMP and TNP-AMP as well as A0.5 and Hill coeﬃcient for
Mg2+ was performed using the GraFit 4 program (Leatherbarrow,
2000). The data on the inhibition of recombinant FBPase by AMP
and TNP-AMP was ﬁtted to the following equation:Table 1
Kinetic parameters for wild-type and mutant forms of liver and muscle FBP
FBPase Activity ratio:
pH 9.3/7.5
kcat (s
1) Km, F1,6-P2
(lM)
Ki for F
(lM)
Wild-type muscle 0.23 23.4 ± 0.7 1.3 ± 0.3 0.16 ± 0
Muscle mutant K20E 0.34 21.1 ± 0.4 1.9 ± 0.4 0.17 ± 0
Muscle double mutant
T177M Q179C
0.37 19.9 ± 0.8 1.5 ± 0.5 0.13 ± 0
Muscle triple mutant
K20E T177M Q179C
0.31 17.6 ± 0.6 1.7 ± 0.4 0.16 ± 0
Wild-type liver 0.34 20.8 ± 0.5 2.1 ± 0.3 0.23 ± 0
Liver mutant E20K 0.38 18.6 ± 0.8 2.3 ± 0.5 0.24 ± 0
Liver double mutant
M177T C179Q
0.42 18.4 ± 0.5 1.9 ± 0.6 0.19 ± 0
Liver triple mutant
E20K M177T C179Q
0.26 21.7 ± 0.3 1.5 ± 0.2 0.18 ± 0v=V max ¼ ½In=In0:5 þ ½I n;
where v is the observed velocity at a speciﬁc concentration of the inhib-
itor, Vmax is the velocity in the absence of the inhibitor, [I] is the con-
centration of the inhibitor, and I0.5 is the concentration of the inhibitor
that causes 50% inhibition. The positive cooperativity the inhibitor is
observed at n (Hill coeﬃcient) > 1, whereas cooperativity is absent
when n = 1.
All other kinetic parameters, such as kcat, Km, Ki for F2,6-P2 and Kis
for F1,6-P2 were calculated with Excel and GraFit assuming an
uncompetitive inhibition of the enzyme by the substrate [16,21].3. Results and discussion
The high sensitivity of free muscle FBPase to AMP inhibi-
tion was hypothesized to be a mechanism protecting muscle
cell against the loss of energy via futile cycling between PFK
and FBPase [25] during muscle contraction. However, con-
trary to well deﬁned mode of the inhibition of liver FBPase
by AMP [27,29–31], the molecular basis of the inhibition of
the muscle isozyme is unknown. Recently, we hypothesized
that the many-fold higher sensitivity of muscle FBPase to
AMP, when compared with the liver isozyme, is predomi-
nantly based upon the stronger binding of the inhibitor to
the muscle enzyme [21]. In the running report, we demonstrate
that the residues 20, 177 and 179 play a crucial role for the dif-
ferent binding of AMP to muscle and liver FBPase.
With the exception of the sensitivity to AMP inhibition, the
kinetic properties of recombinant liver and muscle FBPases do
not diﬀer signiﬁcantly (Table 1, Fig. 1). The most sensitive
wild-type muscle FBPase was inhibited by AMP about 44
times stronger than the wild-type liver FBPase (Table 1,
Fig. 1A). Except the residues 20, 177 and 179, all amino acids
which are involved in AMP binding to the liver isozyme are
also present in the muscle enzyme (Fig. 2). Thus, it might be
expected that inhibition by AMP of muscle FBPase mutants
in which these three amino acid residues are replaced by those
found at the corresponding positions in liver FBPase should be
entirely the same as the inhibition of the wild-type liver en-
zyme. In fact, human muscle FBPases which have been mu-
tated towards human liver FBPase (K20E, double mutant
T177M/Q179C and triple mutant K20E/T177M/Q179C) were
inhibited by AMP about 22, 11 and 26 times weaker, respec-
tively, than the muscle isozyme and only about 2–4 times
stronger than the wild-type liver isozyme (Table 1, Fig. 1A).
Surprisingly, liver FBPase mutated towards the muscle iso-
zyme (E20K, M177T/C179Q and E20K/M177T/C179Q),
which had been hypothesized to be inhibited by AMP identi-ase
2,6-P2 A0.5, Mg
2+
(lM)
Hill coeﬃcient
(Mg2+)
I0.5, AMP
(lM)
Hill coeﬃcient
(AMP)
.01 165 ± 16 1.89 ± 0.21 0.10 ± 0.01 1.78 ± 0.19
.02 149 ± 26 1.78 ± 0.25 2.19 ± 0.05 1.74 ± 0.06
.04 203 ± 34 1.82 ± 0.34 1.14 ± 0.12 1.74 ± 0.23
.03 179 ± 23 1.98 ± 0.31 2.62 ± 0.13 1.83 ± 0.12
.04 199 ± 32 1.83 ± 0.19 4.41 ± 0.10 2.08 ± 0.08
.05 219 ± 41 1.89 ± 0.23 4.82 ± 0.14 2.05 ± 0.10
.04 241 ± 53 1.78 ± 0.19 4.22 ± 0.14 2.03 ± 0.1
.03 187 ± 29 1.91 ± 0.27 3.15 ± 0.15 1.75 ± 0.11
Fig. 1. The inhibition of recombinant FBPases by AMP. Hill coeﬃcients were close to 2.0 for all recombinant FBPases.
Fig. 2. Human muscle FBPase AMP binding pocket. AMP is located
in the middle of the picture at a position in which it is bound to the
human liver enzyme. The diﬀerences between muscle and liver FBPase
are marked in bold. The structure of human muscle FBPase was
constructed on the basis of 1FTA.pdb using SPDBV software [32–34].
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ilarly to the wild-type liver enzyme (Table 1, Fig. 1B). This re-
sult is in contradiction with the data obtained for the muscle
mutants showing the key role of residues 20, 177 and 179 in
the high sensitivity of muscle FBPase to AMP.Fig. 3. Inhibition of recombinant FBPases by TNP-AMP. The concentratio
(I0.5) are presented in bracelets. Hill coeﬃcients were close to unity for all reIn order to distinguish whether the diﬀerences in the inhibi-
tion between wild-type and mutated FBPases were due to a dif-
ferent binding or to a distinct mechanism of allosteric
inhibition, the ﬂuorescent AMP analogue, TNP-AMP [27],
was used. TNP-AMP inhibited FBPases similarly to AMP (Ta-
ble 1, Fig. 3A and B), and the only signiﬁcant diﬀerence was
the absence of cooperativity in the binding of and in the inhi-
bition by the AMP analogue (Figs. 3 and 4A and B) [27]. For
the muscle FBPase K20E and triple mutants, dissociation con-
stants for TNP-AMP were comparable with that determined
for the wild-type liver enzyme (Fig. 4A). This suggests that
the low sensitivity of the muscle triple mutant to AMP inhibi-
tion predominantly originates from the low aﬃnity of the mu-
tant to AMP, which is caused by the substitution of K20 with
E and/or the substitutions of T177 with M and Q179 with C.
Since the binding of TNP-AMP to muscle double mutant
was much stronger (Kd was 0.84 lM, Fig. 4A) than the binding
of TNP-AMP to the muscle single and triple mutants, thus, it
may be presumed that K20 plays the key role in the high aﬃn-
ity of the muscle enzyme to AMP.
In the case of the triple and the double mutant of liver
FBPase, the dissociation constants for TNP-AMP were,
respectively, comparable with that determined for the wild-
type muscle enzyme and about two times lower than that
determined for the wild-type liver enzyme (Fig. 4B). On thens of the inhibitor which causes 50% inhibition of the enzyme activity
combinant FBPases.
Fig. 4. TNP-AMP titration of the recombinant FBPases. Fluorescence of TNP-AMP was observed in the presence of 0.5 lM FBPase. A wavelength
of 410 nm was used for excitation and ﬂuorescence emission was monitored at 535 nm. Dissociation constants (Kd) are presented in bracelets. Hill
coeﬃcients were close to unity for all recombinant FBPases.
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(Fig. 3B) as well as by AMP (Fig. 1B) was relatively weak
and essentially the same as that of the liver isozyme.
If the mechanism of the molecular changes leading to the
inhibition were not impaired by mutations, the stronger bind-
ing of the inhibitor to the liver mutants should result in the
stronger inhibition. The observed discrepancy between the
strength of the inhibitor binding and the level of half-inhibi-
tion, which is especially evident in the case of the liver triple
mutant, suggests that the binding of AMP to the muscle-like
AMP cavity within liver-type domain somehow disturbs the
way of the inhibitory signal transmission.
It has been proposed that AMP inhibits liver FBPase stabi-
lizing an inactive state of mobile loop 52–72 of the adjacent
monomer by its interaction with residues 187–194 and the N-
terminal region [27,30]. Thus, it may be hypothesized that
the association of AMP to the residues T177, Q179 and K20
which are in close proximity to the regions involved in the sta-
bilization of an inactive form of wild-type liver FBPase, im-
pairs their interaction with loop 52–72 and hence, makes the
inhibition weaker.
On the other hand, the observed discrepancy also suggests
that an additional mechanism connected with the diﬀerent
pathway of allosteric signal transmission in muscle FBPase
should be taken into account to explain the strong inhibition
of the muscle isozyme by AMP. An attractive hypothesis is
that the presence of highly conserved N-terminal residues in
muscle FBPase might be responsible for the stronger stabiliza-
tion of an inactive form of the muscle isozyme [21,30].
The main diﬀerence between the liver E20K mutant and
wild-type muscle FBPase is the presence of M177 and C179
in the mutant protein, and it seems obvious that these two res-
idues are solely responsible for the decreased aﬃnity of the mu-
tant enzyme towards the inhibitor (Fig. 4B). Therefore,
although lysine 20 is presumed to be crucial for the strong
binding of AMP to the muscle enzyme, it seems that its pres-
ence is not suﬃcient to overcome the destabilizing eﬀect ex-
erted by residues 177 and 179 on the binding of AMP to
liver FBPase (Fig. 4B).
In summary, the results presented here strongly support the
hypothesis that the presence of K20 and the lack of amino
acids which destabilize the interaction between AMP andFBPase (M177 and C179) is crucial for the much stronger
binding of the inhibitor to muscle FBPase than to the liver iso-
zyme. However, the strong inhibition of the muscle isozyme
does not exclusively arise from the stronger binding of AMP
but also from another mechanism of intramolecular changes
leading to the inhibition.
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